RxDoctor Payments Data

Tonya Goings

Acute Care · Cleveland, OHNPI 1003103102

Payments from drug & device makers

$2,094in general payments, 2019–2025

Across 114 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$959
  • Dexcom, Inc.$370
  • Lilly USA, LLC$185
  • Medtronic$138
  • Tandem Diabetes Care, Inc.$137
  • Currax Pharmaceuticals LLC$128
  • plus $176 from 5 others

What the payments were for

  • Food & beverage$2,093100%
  • Education$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,094 in reported general payments places this provider in the 85th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$23,091
Medicare patients
132
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide226$267,925
JardianceEmpagliflozin218$250,761
TrulicityDulaglutide124$166,415
MounjaroTirzepatide96$116,056
Humulin R U-500 KwikpenInsulin Regular, Human41$64,618
FarxigaDapagliflozin Propanediol54$41,143
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog74$34,985
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/731$31,986
JanuviaSitagliptin Phosphate33$30,914
Humalog Kwikpen U-100Insulin Lispro93$29,591
Lantus SolostarInsulin Glargine,hum.Rec.Anlog181$21,748
TradjentaLinagliptin22$21,649
Fiasp FlextouchInsulin Aspart (Niacinamide)16$20,083
Tresiba Flextouch U-100Insulin Degludec26$18,175
Insulin Lispro Kwikpen U-100Insulin Lispro67$17,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$185$287,827272 claims
Novo NordiskOzempic, Rybelsus, Novolog$68$287,022266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,101 acute care providers in Ohio.

Other acute care in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →